Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | March 09, 2026 | March 12, 2026 |
| Innoviva, Inc.INVA · Entity 4679 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 25,640 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Innoviva, Inc.
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 152,692 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 9,786 · Balance 152,692 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.99 · Expires 2036-05-03 | Direct | 10,000 |
Reported balance
After 2026-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 18,008 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001193125-26-209001 · ownership.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-05-03 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 9,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209001 · ownership.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,692 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 01:13 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 25,640 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026579 · tm268588-1_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 25,640 shares Expires 2036-03-09 F1 · derivative.exercise_date: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:33 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001104659-25-051746 · tm2515701-5_4seq1.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 19, 2025 Filed May 22, 2025 01:33 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051746 · tm2515701-5_4seq1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,906 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:16 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010553 · tm255864-2_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343 Underlying: Common Stock · 54,343 shares Expires 2035-02-05 F1 · derivative.exercise_date: The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:55 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001104659-24-073444 · tm2417570-2_4seq1.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:55 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 13,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073444 · tm2417570-2_4seq1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,829 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:01 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035726 · tm249071-2_4seq1.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 Underlying: Common Stock · 54,343 shares Expires 2034-03-14 F2 · derivative.exercise_date: The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:01 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 39,666 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035726 · tm249071-2_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,666 Underlying: Common Stock · 39,666 shares Expires 2034-03-14 F1 · derivative.exercise_date: The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:53 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 10,461 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129366 · tm2333426-5_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 Underlying: Common Stock · 10,461 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock option vests immediately prior to the Company's 2024 annual shareholders meeting. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:53 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001104659-23-064212 · tm2316873-3_4seq1.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:53 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064212 · tm2316873-3_4seq1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,906 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:51 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $17.79 | $0.00 |
DisclosureSEC source: 0001567619-22-009044 · doc1.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:51 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009044 · doc1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,411 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 19:49 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046444 · tm2212851-3_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| May 14, 2021 Filed May 21, 2021 00:17 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 17,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010831 · doc1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,764 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:46 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001104659-21-046749 · tm2112142-3_4seq1.xml · derivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:13 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-008544 · doc1.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,282 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 24, 2019 Filed May 25, 2019 01:59 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-031864 · a4.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,365 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:10 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005886 · edgar.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,966 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:41 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 10,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002083 · edgar.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,717 Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $23.82 | $0.00 |
DisclosureSEC source: 0000884731-17-000058 · wf-form4_148727265158701.xml · derivative · entry 3 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0000884731-17-000058 · wf-form4_148727265158701.xml · derivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:17 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerCommon Stock | 18,008 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000884731-17-000058 · wf-form4_148727265158701.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2 · price: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 16:55 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $23.82 Strike: $23.82 | $595,500.00 |
DisclosureSEC source: 0000884731-17-000012 · wf-form4_148598612876812.xml · derivative · entry 3 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2017-01-31 F3 · derivative.exercise_date: The stock options granted under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy vest as to approximately one-fourth of the shares underlying the options on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 16:55 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000012 · wf-form4_148598612876812.xml · nonDerivative · entry 2 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,008 F2 · shares: Represents restricted stock units ("RSUs") granted under our 2014 Long-Term Incentive Plan, as amended, and our director compensation policy. The RSUs vest as to approximately one-fourth of the shares underlying the RSUs on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 16:55 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | GrantCommon Stock | 5,508 | $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000012 · wf-form4_148598612876812.xml · nonDerivative · entry 1 Haimovitz Jules · CIK 0001340855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,508 F1 · shares: Represents shares of restricted stock granted in lieu of the annual cash retainer under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy. The shares are subject to a lapsing right of repurchase by the Company that lapses as to approximately one-fourth of the shares on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.